Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioblastoma × azeliragon × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Temozolomide 140 Bevacizumab 80 Radiotherapy 69 Magnetic Resonance Spectroscopy 22 Radiation 18 Irinotecan 18 pembrolizumab 17 Lomustine 16 Carmustine 15 Surgical Procedures, Operative 13 Nivolumab 11 Erlotinib Hydrochloride 11 sargramostim 9 Thalidomide 9 Specimen Handling 9 Chemotherapy, Adjuvant 9 Aminolevulinic Acid 9 Carboplatin 8 Cilengitide 7 Sunitinib 6 Immunoglobulin G 6 Etoposide 6 Disulfides 6 Cyclophosphamide 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Radiotherapy, Intensity-Modulated 5 Radiosurgery 5 Metformin 5 Imatinib Mesylate 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05986851 2024-09-05

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡